Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTO trial of abiraterone with or without ablative radiotherapy in oligometastatic castration-resistant prostate cancer
2016-005284-13Phase 2Completed
- Sponsor
- Università degli Studi di Firenze
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abiraterone in prostate cancer (PCa), sponsored by Università degli Studi di Firenze. Started Feb 2021; status: completed.
02
Drugs
abiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2016-005284-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005284-13.